Literature DB >> 12451085

Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials.

Eric Wooltorton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12451085      PMCID: PMC134141     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  Treating behavioural and psychological signs in Alzheimer's disease.

Authors:  C Ballard; J O'Brien
Journal:  BMJ       Date:  1999-07-17

Review 2.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  Serge Gauthier
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

3.  Caring for elderly people at home: the consequences to caregivers.

Authors:  E Grunfeld; R Glossop; I McDowell; C Danbrook
Journal:  CMAJ       Date:  1997-10-15       Impact factor: 8.262

Review 4.  Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.

Authors:  R S McIntyre; S M McCann; S H Kennedy
Journal:  Can J Psychiatry       Date:  2001-04       Impact factor: 4.356

5.  Risperidone for schizophrenia.

Authors:  J G Edwards
Journal:  BMJ       Date:  1994-05-21

Review 6.  Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease.

Authors:  J E Mintzer
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

Review 7.  Risperidone for the treatment of behavioral and psychological symptoms of dementia.

Authors:  L E Tune
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

8.  Canadian study of health and aging: study methods and prevalence of dementia.

Authors: 
Journal:  CMAJ       Date:  1994-03-15       Impact factor: 8.262

  8 in total
  58 in total

1.  Antipsychotic drugs and diabetes.

Authors:  Roger S McIntyre
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

2.  Potential Association Between Risperidone and Cerebrovascular Events.

Authors:  William V. Bobo; Kenneth F. More
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-06

Review 3.  Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials.

Authors:  Salvatore Gentile
Journal:  Psychopharmacology (Berl)       Date:  2010-07-27       Impact factor: 4.530

Review 4.  Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?

Authors:  Nathan Herrmann; Krista L Lanctôt
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Increased mortality among elderly patients with dementia using atypical antipsychotics.

Authors:  Sonal Singh; Eric Wooltorton
Journal:  CMAJ       Date:  2005-07-13       Impact factor: 8.262

6.  Controversies in behavioral neurology: the use of atypical antipsychotic drugs to treat neurobehavioral symptoms in dementia.

Authors:  Howard S Kirshner
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

7.  Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings.

Authors:  Adeline Gallini; Sandrine Andrieu; Julie M Donohue; Naïma Oumouhou; Maryse Lapeyre-Mestre; Virginie Gardette
Journal:  Eur Neuropsychopharmacol       Date:  2013-09-17       Impact factor: 4.600

Review 8.  Alternatives to atypical antipsychotics for the management of dementia-related agitation.

Authors:  Michael J Passmore; David M Gardner; Yvette Polak; Kiran Rabheru
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 9.  Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.

Authors:  Emilio Sacchetti; Cesare Turrina; Paolo Valsecchi
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

Review 10.  The link between psychosis and aggression in persons with dementia: a systematic review.

Authors:  Denis Shub; Valdesha Ball; Asghar-Ali Ali Abbas; Aruna Gottumukkala; Mark E Kunik
Journal:  Psychiatr Q       Date:  2010-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.